An Open Label Phase 1b/2 Study of Orally Administered PLX 3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Trial Profile

An Open Label Phase 1b/2 Study of Orally Administered PLX 3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Pexidartinib (Primary) ; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Plexxikon
  • Most Recent Events

    • 23 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2018.
    • 23 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Aug 2017.
    • 07 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top